Biocompatibles turns to new target for PC (phosphorylcholine) technology
This article was originally published in Clinica
Executive Summary
UK company Biocompatibles has announced the first element of its strategic review of its business following the sale of its coronary stent business to Abbott earlier this year. The company plans to use its phosphorylcholine (PC) coating for PC Gel Systems - or polyionic complexes - a gel matrix containing PC. The programme, which has a range of applications including drug delivery, combines the company's expertise in polymer systems and drug-eluting devices, Biocompatibles says.